Eone Diagnomics Genome Center Co.Ltd. (KOSDAQ:A245620) announced a private placement of series 1 unregistered unguaranteed private convertible bonds for gross proceeds of KRW 20,000,000,000 on June 21, 2019. The transaction will involve participation from Focus N4 Super Rich Pacific Hedge Fund 1, a fund managed by Mirae Asset Daewoo Co., Ltd. (KOSE:A006800) for KRW 4,900,000,000, AJU Good Growth Support Fund, a fund managed by AJU IB INVESTMENT Co., Ltd. (KOSDAQ:A027360) for KRW 5,000,000,000, Focus TF4 Super Rich Apollo Hedge Fund 1, a fund managed by Korea Investment & Securities Co., Ltd., Investment Arm and Type B Value Up Hedge Fund, a fund managed by NH Investment & Securities Co., Ltd for KRW 2,100,000,000 each, and other investors. The bonds will mature on July 1, 2022.

The bonds will be issued at par and carry no coupon rate and yield to maturity. The bonds are fully convertible into 2,985,520 common shares for 7.62% stake in the company at KRW 6,699 per share. The conversion period will be from July 1, 2020 to June 1, 2022.

The subscription date is June 25, 2019 and the payment date is July 1, 2019.